Drug Profile
Treprostinil dry powder inhalation - MannKind Corporation/United Therapeutics Corporation
Alternative Names: Treprostinil Technosphere®; TreT; Tyvaso DPILatest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator MannKind Corporation
- Developer United Therapeutics Corporation
- Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pulmonary arterial hypertension; Pulmonary hypertension
Most Recent Events
- 22 Aug 2023 United Therapeutics completes the phase-I BREEZE trial in Pulmonary arterial hypertension (Treatment experienced) in USA (Inhalation) (NCT03950739),
- 28 Oct 2022 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension(In the elderly, Treatment-experienced, In adults) in USA (Inhalation, Powder)
- 11 Oct 2022 Updated adverse events data from the phase-III BREEZE trial in Pulmonary arterial hypertension released by United Therapeutics